DiBiase Mary 4
4 · X4 Pharmaceuticals, Inc · Filed Aug 19, 2022
Insider Transaction Report
Form 4
DiBiase Mary
Chief Operating Officer
Transactions
- Sale
Common Stock
2022-08-17−1,713→ 177,896 total
Footnotes (3)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.150 to $1.215, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Of the shares of common stock reported, 164,504 shares represent unvested restricted stock units.